Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C22H26N2O2S.H2O4S |
Molecular Weight | 863.117 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CN1CCC[C@@H]1CC2=CNC3=C2C=C(CCS(=O)(=O)C4=CC=CC=C4)C=C3.CN5CCC[C@@H]5CC6=CNC7=C6C=C(CCS(=O)(=O)C8=CC=CC=C8)C=C7
InChI
InChIKey=IYVZCNNIKYUHHM-WXMGBDCWSA-N
InChI=1S/2C22H26N2O2S.H2O4S/c2*1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20;1-5(2,3)4/h2*2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3;(H2,1,2,3,4)/t2*19-;/m11./s1
Molecular Formula | H2O4S |
Molecular Weight | 98.078 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H26N2O2S |
Molecular Weight | 382.519 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/10193663 | http://www.migraines.org/treatment/pro_rlpx.htm
Curator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/10193663 | http://www.migraines.org/treatment/pro_rlpx.htm
Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11069595
Curator's Comment: Known to be CNS penetrant in rats. Human data not available. It was concluded that eletriptan, acting on perikarya and both the peripheral and the central axon terminals of primary sensory neurons, exerts its antimigraine effect by an agonist action on 5-HT1B/1D receptors throughout the entire trigeminal system, probably by passing the blood-brain-barrier because of its lipophilic character.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P28221 Gene ID: 3352.0 Gene Symbol: HTR1D Target Organism: Homo sapiens (Human) |
0.92 nM [Kd] | ||
Target ID: P28222 Gene ID: 3351.0 Gene Symbol: HTR1B Target Organism: Homo sapiens (Human) |
3.14 nM [Kd] | ||
Target ID: P30939 Gene ID: 3355.0 Gene Symbol: HTR1F Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RELPAX Approved UseRELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. Launch Date1.04086077E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
183.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
200.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
46.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
94.72 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1278 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
1282 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
291.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
575.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4.58 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4.63 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29497279 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ELETRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15% |
ELETRIPTAN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (0.4%) Sources: Page: Study 102Dizziness (0.4%) Asthenia (0.3%) Chest pain (0.3%) Headache (0.2%) Vomiting (0.2%) Hypertonia (0.2%) Paresthesia (0.2%) Somnolence (0.2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | 0.2% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Hypertonia | 0.2% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Paresthesia | 0.2% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Somnolence | 0.2% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Vomiting | 0.2% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Asthenia | 0.3% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Chest pain | 0.3% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Dizziness | 0.4% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Nausea | 0.4% Disc. AE |
80 mg 1 times / day single, oral (typical) Recommended Dose: 80 mg, 1 times / day Route: oral Route: single Dose: 80 mg, 1 times / day Sources: Page: Study 102 |
unhealthy, 41.9 n = 312 Health Status: unhealthy Condition: migraine Age Group: 41.9 Sex: M+F Population Size: 312 Sources: Page: Study 102 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://dmd.aspetjournals.org/content/31/7/861.long Page: 9.0 |
inconclusive | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_BioPharmr.pdf#page=9 Page: 9.0 |
major | yes (co-administration study) Comment: when administered with ketoconazole, Cmax and AUC increased by 2.7-fold and 5.9-fold, respectively; when administered with verapamil, Cmax and AUC increased by 2.2-fold and 2.7-fold, respectively; when administered with fluconazole, Cmax and AUC increased by 1.4-fold and 2-fold, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_BioPharmr.pdf#page=9 Page: 9.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_BioPharmr.pdf#page=9 Page: 9.0 |
minor | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_BioPharmr.pdf#page=9 Page: 9.0 |
minor |
PubMed
Title | Date | PubMed |
---|---|---|
Eletriptan: pharmacological differences and clinical results. | 2001 |
|
Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. | 2001 Aug 17 |
|
Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. | 2001 Dec |
|
Safety and rational use of the triptans. | 2001 Jul |
|
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. | 2001 Nov 17 |
|
Spotlight on rizatriptan in migraine. | 2002 |
|
Gateways to Clinical Trials. | 2002 Apr |
|
Sumatriptan versus eletriptan: which is best? | 2002 Dec |
|
Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. | 2002 Feb |
|
[Migraine has to be treated. Otherwise a stroke threatens]. | 2002 Feb 14 |
|
Tripstar: a comprehensive patient-based approach to compare triptans. | 2002 Jan |
|
[New triptanes in control of migraine attacks. More rapid onset of action--more efficient reduction of pain]. | 2002 Jan 24 |
|
Mechanisms of action of the 5-HT1B/1D receptor agonists. | 2002 Jul |
|
Pharmacological treatments for acute migraine: quantitative systematic review. | 2002 Jun |
|
Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration. | 2002 May |
|
The pharmacokinetics and safety of single escalating oral doses of eletriptan. | 2002 May |
|
Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. | 2002 May |
|
Gateways to clinical trials. | 2002 Oct |
|
Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. | 2002 Oct |
|
Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. | 2002 Oct 25 |
|
Eletriptan Pfizer. | 2002 Sep |
|
Gateways to Clinical Trials. | 2002 Sep |
|
Current perspectives on effective migraine treatments: are small clinical differences important for patients? | 2003 |
|
Newer formulations of the triptans: advances in migraine management. | 2003 |
|
Eletriptan (relpax) for migraine. | 2003 Apr 28 |
|
[Treatment of migraine: an update]. | 2003 Jan |
|
[Pharmacological, pharmacokinetic and clinical profile of eletriptan (Relpax), a new triptan for migraine]. | 2003 Jul |
|
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. | 2003 Jul |
|
The evolving management of migraine. | 2003 Jun |
|
Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. | 2003 Mar |
|
[Highly selective beginning. Associated symptoms and side effects in retrospect]. | 2003 May 26 |
|
[Improved pharmacokinetics. Fast tryptan with sustained response]. | 2003 May 26 |
|
Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. | 2003 Nov |
|
Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. | 2003 Oct |
|
Encapsulated sumatriptan is not bioequivalent to commercial sumatriptan. | 2003 Sep |
|
The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. | 2004 Feb |
|
[Recent progress in therapy for migraine headache]. | 2004 Feb 10 |
|
Neuronal expression and regulation of CGRP promoter activity following viral gene transfer into cultured trigeminal ganglia neurons. | 2004 Jan 30 |
|
Gateways to clinical trials. | 2004 Jan-Feb |
|
Effect of high-dose intravenous eletriptan on coronary artery diameter. | 2004 Jul |
|
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. | 2004 Jun |
|
Gateways to clinical trials. | 2004 Mar |
|
Cost considerations of acute migraine treatment. | 2004 Mar |
|
Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. | 2004 May |
|
Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. | 2004 May |
|
[Spanish contribution to the clinical development of eletriptan: an analysis of controlled studies]. | 2004 Oct |
|
No effect of eletriptan administration during the aura phase of migraine. | 2004 Oct |
|
[Triptans in migraine: from clinical view]. | 2004 Sep |
|
Gateways to clinical trials. | 2004 Sep |
|
Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). | 2004 Sep |
Sample Use Guides
The maximum recommended single dose of Relpax (eletriptan hydrobromide) is 40 mg. If after the initial dose, headache improves but then returns, a repeat dose may be beneficial. If a second dose is required, it should be taken at least 2 hours after the initial dose. If the initial dose is ineffective, controlled clinical trials have not shown a benefit
of a second dose to treat the same attack. The maximum daily dose should not exceed 80 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15185063
The 5-hydroxytryptamine (5-HT) receptor mediation of the contraction in guinea-pig iliac arteries moderately precontracted by prostaglandin F2alpha (PGF2alpha) was characterized in vitro using eletriptan. Eletriptan contracted guinea-pig iliac arteries and the concentration-response curve for eletriptan was biphasic (first phase: 0.01-3 uM, pD2 approximately 6.6; second phase: greater or equal 10 uM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:24:33 UTC 2023
by
admin
on
Fri Dec 15 16:24:33 UTC 2023
|
Record UNII |
AMM8PSU28B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9832589
Created by
admin on Fri Dec 15 16:24:33 UTC 2023 , Edited by admin on Fri Dec 15 16:24:33 UTC 2023
|
PRIMARY | |||
|
219790-71-3
Created by
admin on Fri Dec 15 16:24:33 UTC 2023 , Edited by admin on Fri Dec 15 16:24:33 UTC 2023
|
PRIMARY | |||
|
AMM8PSU28B
Created by
admin on Fri Dec 15 16:24:33 UTC 2023 , Edited by admin on Fri Dec 15 16:24:33 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |